
Uber Just Made a Huge Investment in Its Robotaxi Future. Here's What Investors Need to Know.
Uber just allied with EV maker Lucid and autonomous vehicle technology start-up Nuro.
The partnership will help give the company more control over its destiny as the world slowly shifts to robotaxis.
It's a bold move that comes with some risk, but a smart one to have made.
10 stocks we like better than Uber Technologies ›
Uber Technologies (NYSE: UBER) is going all-in on autonomous vehicles. The company just committed to a massive multiyear partnership with electric vehicle (EV) maker Lucid (NASDAQ: LCID) and self-driving start-up Nuro in a move that could reshape its future.
As part of this new alliance, Uber will make a $300 million investment in Lucid and a separate, "multi-hundred-million-dollar" investment in Nuro. It will then look to deploy at least 20,000 robotaxis built by Lucid and equipped with Nuro's Level 4 autonomous driving tech over the next six years.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
This isn't Uber's first foray into robotaxis, but it is its biggest direct bet on owning an autonomous fleet. The company already had partnerships with Alphabet 's (NASDAQ: GOOGL)(NASDAQ: GOOG) Waymo and May Mobility in the U.S., WeRide in Europe and elsewhere, and Pony.ai in the Middle East.
Unlike prior partnerships where Uber mostly provided the user-facing platform, this time it -- and in some cases third-party fleet partners -- will own and operate the vehicles. It's a major shift in strategy and signals that Uber wants more control as the ride-hailing market starts to shift to robotaxis.
For its robotaxi fleet, Uber will use Lucid's Gravity SUV, which will then be equipped with Nuro's autonomous vehicle system. The Gravity's long 450-mile range and hardware redundancies make it a great option to use as a robotaxi. Lucid and Nuro have already begun testing prototypes in Las Vegas.
Uber makes a big bet in a competitive market
This is an important move for Uber. Robotaxis aren't some futuristic vision anymore, they are already on the streets and being used. Waymo is delivering paid autonomous rides in several U.S. cities, while Tesla (NASDAQ: TSLA) just launched a robotaxi pilot in Austin, Texas.
The risk for a company like Uber, as the world begins to shift toward robotaxis, is that it could get left out of the picture. If Alphabet and Tesla decide they just want to offer driverless rides directly through their own apps, Uber risks being left out of the equation in the future.
As such, Uber's partnership with Nuro and Lucid is a way for it to get more control over its future. The company isn't just licensing Nuro's technology and buying vehicles from Lucid; it's directly investing in both. This is both a defensive and an offensive move, but it was smart to make.
However, this bet does not come without risks. Nuro, for its part, has had to reinvent itself. The company was originally focused on using its technology with delivery robots, but after burning through a boatload of cash, it shifted its strategy to licensing its technology to automakers and other companies. This is its first big licensing deal, so we'll have to see how it plays out.
Uber's platform advantage
At the end of the day, Uber likely isn't going to beat out Tesla or Alphabet on the technology front; however, the company does have some nice advantages. The company has built a strong brand and is a popular app on hundreds of millions of people's phones around the globe. It also has decades of routing and pricing data, as well as expertise in how to manage vehicle supply in a dynamic demand environment. So while a company like Waymo can develop a top-notch autonomous vehicle system, Uber has strong distribution already in place and knows how to operate a fleet.
That's why Waymo has teamed up with Uber in cities like Austin and Atlanta. Waymo handles the vehicles and technology, while Uber runs the customer experience. Thus far, the partnership appears to be going well. For example, Uber has said that the average Waymo vehicle in Austin is busier than 99% of its human drivers.
With this new Lucid-Nuro partnership, Uber will take this concept to the next level by having more control over vehicle ownership. It's a smart move, but we'll also see how it impacts its other partnerships, including with Waymo.
A strong core business gives Uber time
Outside of its robotaxi partnerships, Uber's core business is currently running on all cylinders. The company is profitable and generating strong free cash flow. Meanwhile, both its ride-hailing and delivery segments are growing nicely. This will give it time to get its robotaxi fleet off the ground and running.
In the first quarter of 2025, its total trips rose 18%, and revenue climbed 14% to $11.5 billion. Mobility revenue increased 15% to $6.5 billion, while delivery grew 18% to $3.8 billion. Profitability metrics are growing even faster. In mobility, EBITDA grew 19% to $1.8 billion, while its delivery EBITDA soared 45% to $763 million. Importantly, the company generated $2.3 billion in free cash flow in the quarter, up 66% from a year ago.
The road ahead
That said, the future is clearly all about robotaxis.
Building out a robotaxi fleet -- even with partners -- costs a lot of money and requires strong execution. Lucid won't begin producing the vehicles until late 2026, and it will take time for production to ramp up. Meanwhile, competition is likely only going to heat up in the interim.
That said, Uber isn't sitting still, and it's making multiple bets in the space to make sure it does not get left standing on the side of the road as the market shifts.
While not without its risks, this is an important deal for Uber. If the company can become a leader in the robotaxi market, the payoff could be enormous. Investors should be watching closely.
Should you invest $1,000 in Uber Technologies right now?
Before you buy stock in Uber Technologies, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Uber Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $634,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,799!*
Now, it's worth noting Stock Advisor's total average return is 1,037% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
27 minutes ago
- Globe and Mail
Is Viking Therapeutics the Next Big Biotech Bet?
Explore the exciting world of Viking Therapeutics (NASDAQ: VKTX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 9, 2025. The video was published on Aug. 1, 2025. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025


Globe and Mail
an hour ago
- Globe and Mail
Why Arm Holdings Stock Sank by Over 15% This Week
Key Points The company's second-quarter results displeased many investors. They also inspired some analyst price target cuts. 10 stocks we like better than Arm Holdings › Arm Holdings (NASDAQ: ARM) felt something like an unwanted limb over the past few days, largely because of an earnings report that struck the wrong chord with more than a few investors. Several analyst price target cuts only highlighted this disappointment. Ultimately, according to data compiled by S&P Global Market Intelligence, the specialty tech company's shares plummeted by over 15% this week. Top-line growth, bottom-line slide U.K.-based Arm published its results for the first quarter of its fiscal 2026 on Wednesday. The report showed that the company managed to increase its total revenue by 12% year over year to slightly more than $1.05 billion. That was largely due to a 25% increase in royalty revenue, which landed at $585 million, and despite a 1% slump in licensing revenue to $468 million. Non- GAAP (adjusted) net income traveled in the opposite direction. It fell to $374 million, or $0.35 per share, compared with the year-ago profit of $419 million. With those numbers, Arm met the consensus analyst estimate for profitability, although it missed slightly on revenue -- pundits following the stock were expecting it to earn $1.06 billion. More of a concern for investors was management's guidance for the company's current (second) quarter. Its forecast is for $1.01 billion to $1.11 billion in revenue, which, if achieved, would be down or, at best, essentially flat over the first quarter. Meanwhile, adjusted earnings were forecast at $0.29 to $0.37. Bearish analyst moves Although analyst reactions to the quarter were mixed, enough pundits trimmed their price targets to affect sentiment on the stock. UBS 's Timothy Arcuri, for one, shaved his fair value assessment to $175 per Arm share from his preceding $185. He did, however, maintain his buy recommendation. Lee Simpson of Morgan Stanley acted similarly, reducing the price target to $180 per share from $194 while keeping an overweight (buy, in other words) rating intact. Should you invest $1,000 in Arm Holdings right now? Before you buy stock in Arm Holdings, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Arm Holdings wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $625,254!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,090,257!* Now, it's worth noting Stock Advisor's total average return is 1,036% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025


Globe and Mail
2 hours ago
- Globe and Mail
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the 'Company') (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Aug. 1, 2025, the Compensation Committee of the Company's Board of Directors (the 'Compensation Committee') granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 39,000 shares of common stock to 5 new employees under the Company's 2024 Inducement Plan. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $10.59 per share, the Company's closing sales price on Aug. 1, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees' continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company's 2024 Inducement Plan and the terms and conditions of an applicable stock option agreement covering the grant. About Immunome, Inc. Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. For more information, visit